HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0285251 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Samar M Alanazi und 7 weiteren Autor:innen. Beteiligte Einrichtung: James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, United States of America. Hauptthemen laut MEDLINE: Breast Neoplasms, Nonmuscle Myosin Type IIA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
HER2 is over-expressed in around 15% to 20% of breast cancers. HER3 plays a critical role in HER2 mediated tumorigenesis. Increased HER3 transcription and protein levels occur upon inhibition of HER2. We aimed to identify proteins that bound to HER3 upon inhibition of the HER family with the pan-HER inhibitor neratinib in HER2+ breast cancer cells. Immunoprecipitation of HER3 followed by mass spectrometry experiments found non-muscle myosin IIA (NMIIA) increased upon neratinib treatment relative to vehicle DMSO treatment. MYH9 is the gene that encodes for the heavy chain of NMIIA. Breast cancer patients with high MYH9 were significantly associated with a shorter disease specific survival compared to patients with low MYH9 expression from the METABRIC cohort of patients. In addition, high MYH9 expression was associated with HER2+ tumors from this cohort. Immunoblots of whole cell lysates of BT474 and MDA-MB-453 HER2+ breast cancer cells demonstrated elevated HER3 and NMIIA protein levels upon neratinib treatment for 24 hours. To examine the role of NMIIA in HER2+ breast cancer, we modulated NMIIA levels in BT474 and MDA-MB-453 cells using doxycycline inducible shRNA targeting MYH9 . MYH9 knockdown reduces HER3 protein levels and concomitant reduction in downstream P-Akt. In addition, loss of MYH9 suppresses cell growth, proliferation, migration, and invasion. Our data reveals that NMIIA regulates HER3 and loss of NMIIA reduces HER2+ breast cancer growth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, United States of America.
- Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
ORCID-Profile: Wasim Feroz, Joan T Garrett
Zitieren
APA
Alanazi, S. M., Feroz, W., Mishra, R., Kilroy, M. K., Patel, H., Yuan, L., Storr, S. J., & Garrett, J. T. (2023). HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers. PLOS ONE. https://doi.org/10.1371/journal.pone.0285251
Vancouver
Alanazi SM, Feroz W, Mishra R, Kilroy MK, Patel H, Yuan L, et al. HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers. PLOS ONE. 2023. doi:10.1371/journal.pone.0285251
BibTeX
@article{Alanazi2023,
author = {Alanazi, Samar M and Feroz, Wasim and Mishra, Rosalin and Kilroy, Mary Kate and Patel, Hima and Yuan, Long and Storr, Sarah J and Garrett, Joan T},
title = {HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0285251}
}
EUVIMED